RapidPulse Receives FDA Approval to Begin IDE Study in Ischemic Stroke Using Innovative Cyclic Aspiration System – Recently Completed Clinical Trial Shows Significantly Higher First Pass and Frontline Success Rates

Study Investigators Conclude RapidPulse® Precise Cyclic Aspiration Is Highly Effective and Safe for Ischemic Stroke Large Vessel Occlusions

RapidPulse investors extend Series A funding with $10M

The company is gearing up for FDA submission in the fourth quarter of 2023

RapidPulse Feasibility Study Results Presented at European Stroke Organization Committee Annual Meeting

Data from five hospitals showed FPE TICI≥2c rate was 60% with RapidPulse®...only 38.5% with standard aspiration

RapidPulse, developer of a device for treating strokes, raises $10.5M

Its technology may double the success rate of quick clot removal leading to better patient outcomes

RapidPulse Raises Funding for Ischemic Stroke Therapies

First human use cases results show RapidPulse® enables doctors to get first pass effect results of TICI≥2c in 69% of cases…data presented at SNIS 2022

Stroke device maker RapidPulse spins out of Syntheon incubator

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke